Thread by @JamesTodaroMD

1/ Here is my summary of the relevant points from the breaking open-label clinical trial on the use of hydroxychloroquine (HCQ) and azithromycin in the treatment of COVID-19 by Didier Raoult, MD/PhD. @DiderRaoult

2/ Trial included 36 adult patients, 26 received HCQ & 16 controls. Six out of 42 patients meeting inclusion criteria lost to follow up. (All from treatment group: 3 transferred to ICU, 1 death, 1 left hospital, 1 stopped HCQ bc nausea. No control patients lost to follow-up.)

3/ HCQ-treated patients average age 51.2 yrs vs control patients average age of 37.3 yrs. Six patients receiving HCQ received azithromycin on day 1 (unclear how certain patients were selected to receive azithromycin).

4/ Control group:
-No HCQ

HCQ treatment group:
-Oral HCQ sulfate, 200mg three times a day for 10 days

HCQ + Azithromycin treatment group:
-Oral HCQ sulfate, 200mg three times a day for 10 days
-Oral azithromycin, 500mg on day 1, followed by 250mg daily for 4 days

5/ Results on Day 6:
-12.5% of control patients virologically cured
-57.1% of HCQ treated patients virologically cured
-100% of HCQ + Azithromycin patients virologically cured

6/ Of note:
a) This is not my research.
b) This a small non-randomized clinical trial which had patient dropout in the treatment group.
c) I look forward to more clinical data on this treatment.
d) Please follow the recommendations of your doctor. This is not medical advice.